2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

also include the assessment of potential long-term toxicities
in patients, which might be more relevant in individuals
receiving brentuximab vedotin as part of curative therapy
at earlier time points. The incidence of bleomycin-induced
pulmonary toxicity in patients receiving ABVD/brentuximab
vedotin (28%) is unusually high for this population. The
standard risk of bleomycin-induced pulmonary toxicity
with six cycles of ABVD is approximately 2% in patients
without other pulmonary risk factors. These data, combined
with the earlier data from Blum and the CALGB indicating
a specific V/F polymorphism in the FcgammaRIIIa gene
underlying susceptibility, 15 suggest that more research on
intrinsic risk factors for pulmonary toxicity should be undertaken
and that the ideal combination platform for brentuximab
vedotin must also avoid concurrent use of other
Authors’ Disclosures of Potential Conflicts of Interest
Employment or
Leadership Consultant or Stock
Author
Positions Advisory Role Ownership Honoraria
Catherine S. M.
Diefenbach
Seattle Genetics Seattle Genetics
John P. Leonard Seattle Genetics
1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American
Cancer Society, 2009.
2. SEER Cancer Statistics Review 2001-2008. National Cancer Institute.
www.seer.cancer.gov.
3. Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with
Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol. 1997;15:
528-534.
4. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage
combination chemotherapy in patients relapsing with Hodgkin’s disease after
combination chemotherapy: the low probability for cure. J Clin Oncol.
1992;10:210-218.
5. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer
J Clin. 2009;59:225-249.
6. Aldinucci D, Gloghini A, Pinto A, et al. The classical Hodgkin’s lymphoma
microenvironment and its role in promoting tumour growth and
immune escape. J Pathol. 2010;221:248-263.
7. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin’s
lymphoma: increasing evidence of the importance of the microenvironment.
J Clin Oncol. 2011;29:1812-1826.
8. Farrell K, Jarrett RF. The molecular pathogenesis of Hodgkin lymphoma.
Histopathology. 2011;58:15-25.
9. Nadali G, Vinante F, Ambrosetti A, et al. Serum levels of soluble CD30
are elevated in the majority of untreated patients with Hodgkin’s disease and
correlate with clinical features and prognosis. J Clin Oncol. 1994;12:793-797.
10. Younes A, Carbone A. CD30/CD30 ligand and CD40/CD40 ligand in
malignant lymphoid disorders. Int J Biol Markers. 1999;14:135-143.
11. Gardner LJ, Polski JM, Evans HL, et al. CD30 expression in follicular
lymphoma. Arch Pathol Lab Med. 2001;125:1036-1041.
12. Horie R, Watanabe T. CD30: expression and function in health and
disease. Semin Immunol. 1998;10:457-470.
13. Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of
SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large
cell lymphoma. Br J Haematol. 2009;146:171-179.
14. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an
anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and
anaplastic large-cell lymphoma. J Clin Oncol. 2007;25:2764-2769.
15. Blum KA, Jung SH, Johnson JL, et al. Serious pulmonary toxicity in
patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine,
and liposomal doxorubicin is associated with an Fc�RIIIa-158 V/F polymorphism.
Ann Oncol. 2010;21:2246-2254.
16. Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking
and cysteine protease metabolism confer target-specific cytotoxicity by
peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281:
10540-10547.
166
REFERENCES
agents with overlapping toxicities. Given the relatively high
incidence of peripheral sensory neuropathy seen in phase II
trials, attention should also be paid to this side effect during
long-term therapy, although the data thus far suggest that
this symptom improves in most patients with the cessation
of therapy.
As we gain greater scientific understanding of the role of
CD30 signaling, the immunologic microenvironment, and
mechanisms of tumor resistance in CD30-positive lymphomas,
one may anticipate that even more rationally designed
treatment regimens will emerge. Despite the relative success
achieved for most patients with HL with standard,
largely empirically designed regimens, brentuximab vedotin
use provides an example of the direction of future collaborative
and translational efforts.
Research
Funding
DIEFENBACH AND LEONARD
Expert
Testimony
Other
Remuneration
17. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an
anti-CD30-monomethyl auristatin E conjugate with potent and selective
antitumor activity. Blood. 2003;102:1458-1465.
18. McEarchern JA, Kennedy D, McCormick R, et al. Activity of SGN-35 in
preclinical models of combination therapy and relapse prevention. Haematol.
2010;95 (suppl; abstr 49)
19. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin
(SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:
1812-1821.
20. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly
dosing study of brentuximab vedotin in patients with relapsed/refractory
CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18:248-255.
21. Chen R, Gopal AK, Smith SE, et al. Results of a pivotal Phase 2 study
of brentuximab vedotin (SGN-35) in patients with relapsed or refractory
Hodgkin lymphoma. Blood . 2010;116:21 (suppl; abstr 283).
22. Chen RW, Gopal AK, Smith SE, et al. Results from a pivotal phase II
study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory
Hodgkin lymphoma (HL). J Clin Oncol. 2011;29:15 (suppl; abstr 8031).
23. Pro B, Advani R, Brice P, et al. Durable remissions with brentuximab
vedotin (SGN-35): Updated results of a phase II study in patients with
relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
J Clin Oncol. 2011;29;15 (suppl; abstr 8032).
24. Advani RH, Shustov AR, Brice P, et al. Brentuximab vedotin (SGN-35)
in patients with relapsed or refractory systemic anaplastic large cell lymphoma:
A Phase 2 study update. Blood. 2011;118;21 (suppl; abstr 443).
25. Foyil KV, Kennedy DA, Grove LE, et al. Extended retreatment with
brentuximab vedotin (SGN-35) maintains complete remission in patient with
recurrent systemic anaplastic large-cell lymphoma. Leuk Lymphoma. 2012;
53:506-507
26. Bartlett N, Grove LE, Kennedy DA, et al. Objective responses with
brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic
malignancies: A case series. J Clin Oncol. 2010;28:15 (suppl; abstr 8062).
27. Younes A, Connors JM, Park SI, et al. Frontline therapy with brentuximab
vedotin combined with ABVD or AVD in patients with newly diagnosed
advanced stage Hodgkin lymphoma). Blood. 2011;118;21 (suppl; abstr 955).
28. Moskowitz C. Risk-adapted therapy for relapsed and refractory lymphoma
using ICE chemotherapy. Cancer Chemother Pharmacol. 2002;49:1
(suppl; S9-12)
29. Chen RW, Forman SJ, Palmer J, et al. Brentuximab vedotin (SGN-35)
enables successful reduced intensity allogeneic hematopoietic cell transplantation
in relapsed/refractory Hodgkin lymphoma. Blood. 2011;118 (supple;
abstr 664).